id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-355017-934v85q1	Pérez-Cameo, Cristina	Serosurveys and convalescent plasma in COVID-19	2020-05-01		.txt	text/plain	853	50	51	Based on the WHO interim guidance developed for the 2014 Ebola outbreak [3] , convalescent plasma has advantages over other proposed treatment: it requires low technology (and therefore it can be produced where required independent of pharmaceutical companies), it is low cost and its production is easily scalable as long as there are sufficient donors. Furthermore, the real number of convalescent patients may be much greater than the number based on the recovery of previously identified patients because of the existence of asymptomatic and mild infections. Targeting populations at high risk of exposure such as contacts or health workers and self-identification of potentially convalescent patients using questionnaires could easily lead to as many plasma donors as required before the number of contagions peaks. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks.	./cache/cord-355017-934v85q1.txt	./txt/cord-355017-934v85q1.txt